Cancer Therapy

Boromycin may sensitize tumor cells to anti-cancer agents

Published in Cancer Weekly, January 4th, 2005

The polyether-macrolide antibiotic boromycin may sensitize tumor cells to the effects of anti-cancer agents.

"The DNA-damaging agent bleomycin arrests the cell cycle at the G₂ phase of Jurkat cells defective in the G₁ checkpoint, and microtubule-acting colchicine arrests it at the M phase," scientists in Japan explained.

"Boromycin itself, an actinomycete metabolite, showed no effect on the cell cycle status of Jurkat cells at least up to 340 nM," in a study conducted by M. Arai and coauthors at Kitasato University. "However, the compound (3.4-340 nM) was found to abrogate bleomycin-induced G₂ arrest even at 3.4...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-01-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry